What's the Difference Between Ozempic and Semaglutide? The Complete Brand vs Generic vs Compounded Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic IS semaglutide. Semaglutide is the active drug molecule; Ozempic is Novo Nordisk's brand name for their FDA-approved 0.5 mg, 1 mg, and 2 mg formulations approved for type 2 diabetes.
• The confusion exists because three different FDA-approved semaglutide products exist (Ozempic, Wegovy, Rybelsus), each approved for different indications at different doses, plus compounded semaglutide from pharmacies.
• Compounded semaglutide contains the same active ingredient as Ozempic but is prepared by a licensed pharmacy, not manufactured by Novo Nordisk, and is not FDA-approved as a finished product.
• Price difference is the main practical distinction: brand Ozempic costs $900 to $1,000 per month without insurance; compounded semaglutide typically costs $200 to $400 per month.

Direct answer (40-60 words)

Ozempic and semaglutide are the same molecule. Semaglutide is the drug's chemical name; Ozempic is Novo Nordisk's brand name for their FDA-approved injectable formulation at 0.5 mg, 1 mg, and 2 mg weekly doses for type 2 diabetes. The difference is regulatory status, manufacturer, dose options, and cost, not the active ingredient itself.

Table of contents

1. The naming confusion: why this question exists
2. What semaglutide actually is (the molecule)
3. The three FDA-approved semaglutide products and what each is approved for
4. Brand Ozempic vs compounded semaglutide: the real differences
5. What most articles get wrong about "generic" semaglutide
6. The dose and indication matrix: which product for which use
7. Compounded semaglutide during the FDA shortage: legal status and quality questions
8. Price comparison: brand vs compounded across dose levels
9. Insurance coverage differences between Ozempic and compounded versions
10. The clinical equivalence question: do they work the same?
11. When to use brand Ozempic vs when compounded semaglutide makes sense
12. FAQ
13. Sources

The naming confusion: why this question exists

The question "what's the difference between Ozempic and semaglutide" reveals a structural confusion in how GLP-1 medications are marketed and prescribed. The confusion has three sources:

First, multiple brand names for the same molecule. Novo Nordisk sells semaglutide under three different brand names depending on indication and dose:

• Ozempic (injectable, 0.5 mg to 2 mg weekly, FDA-approved for type 2 diabetes)
• Wegovy (injectable, up to 2.4 mg weekly, FDA-approved for weight management)
• Rybelsus (oral tablet, 7 mg to 14 mg daily, FDA-approved for type 2 diabetes)

All three contain semaglutide. The brand name changes based on FDA approval category, not drug composition.

Second, off-label prescribing blurs the lines. Ozempic is FDA-approved only for diabetes, but physicians prescribe it off-label for weight loss at doses up to 2 mg weekly. Wegovy is approved for weight loss but frequently unavailable due to supply constraints. Patients hear "I'm on Ozempic for weight loss" and "I'm on semaglutide for weight loss" used interchangeably because they're describing the same clinical situation with different terminology.

Third, compounded semaglutide entered the market. During the 2022 to 2024 Wegovy and Ozempic shortages, the FDA allowed compounding pharmacies to prepare semaglutide formulations under Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies sell "semaglutide" (the chemical name) rather than "Ozempic" (the brand name they don't have rights to). Patients now encounter both brand Ozempic from Novo Nordisk and compounded semaglutide from pharmacies, which look different, cost different amounts, and come from different sources but contain the same active drug.

The result is that "Ozempic" and "semaglutide" are used interchangeably in conversation but refer to legally and commercially distinct products in the healthcare system.

What semaglutide actually is (the molecule)

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It's a 31-amino-acid peptide with 94% structural homology to native human GLP-1. The modifications from native GLP-1 include an amino acid substitution at position 8 (alanine to aminoisobutyric acid) and attachment of a C18 fatty acid chain via a linker, which allows the molecule to bind to albumin in the bloodstream and extend its half-life to approximately 7 days (Lau et al., Journal of Medicinal Chemistry, 2015).

The extended half-life is what makes once-weekly dosing possible. Native GLP-1 has a half-life of 2 to 3 minutes and requires continuous infusion to maintain therapeutic levels. Semaglutide's albumin-binding modification keeps it circulating long enough for weekly subcutaneous injection.

Semaglutide works by:

1. Activating GLP-1 receptors in pancreatic beta cells, which increases insulin secretion in a glucose-dependent manner
2. Suppressing glucagon secretion from pancreatic alpha cells
3. Slowing gastric emptying, which reduces post-meal glucose spikes and increases satiety
4. Acting on appetite centers in the hypothalamus to reduce hunger and food intake

The weight-loss effect comes primarily from mechanisms 3 and 4. The glucose-lowering effect comes from mechanisms 1 and 2. Both effects happen with the same molecule at any dose; the difference is magnitude.

This is the same semaglutide molecule whether it's in an Ozempic pen, a Wegovy pen, a Rybelsus tablet, or a compounded vial. The chemical structure doesn't change. What changes is formulation, dose, delivery method, and regulatory approval.

The three FDA-approved semaglutide products and what each is approved for

Product	Manufacturer	Form	Approved doses	FDA indication	Approval date
Ozempic	Novo Nordisk	Subcutaneous injection	0.5 mg, 1 mg, 2 mg weekly	Type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease	December 2017 (initial); March 2022 (2 mg dose)
Wegovy	Novo Nordisk	Subcutaneous injection	0.25 mg to 2.4 mg weekly (titration schedule)	Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity	June 2021
Rybelsus	Novo Nordisk	Oral tablet	7 mg, 14 mg daily	Type 2 diabetes	September 2019

The FDA approval language matters because it determines what insurance will cover and what physicians can prescribe on-label. Ozempic is approved for diabetes, not weight loss. Wegovy is approved for weight loss, not diabetes. Physicians prescribe both off-label for the non-approved indication routinely, but insurance coverage follows the FDA label.

The dose ranges overlap but aren't identical. Ozempic maxes out at 2 mg weekly. Wegovy goes to 2.4 mg weekly. The 2.4 mg dose was studied specifically for weight loss in the STEP trial program and showed superior weight reduction compared to 1 mg (Wilding et al., New England Journal of Medicine, 2021). The 2 mg Ozempic dose was added later based on diabetes efficacy data, not weight-loss data.

Rybelsus is oral semaglutide, which requires a different formulation. The tablet includes a permeation enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to allow GI absorption of the peptide, which normally degrades in the stomach. Oral bioavailability is roughly 1%, so the daily doses (7 mg, 14 mg) are higher than the weekly injectable doses to achieve comparable drug exposure (Buckley et al., Clinical Pharmacokinetics, 2018).

All three products are manufactured by Novo Nordisk under FDA-approved New Drug Applications (NDAs). Compounded semaglutide is not.

Brand Ozempic vs compounded semaglutide: the real differences

The table below shows the practical distinctions between brand Ozempic and compounded semaglutide from a licensed 503A or 503B pharmacy.

Feature	Brand Ozempic	Compounded semaglutide
Active ingredient	Semaglutide	Semaglutide (same peptide sequence)
Manufacturer	Novo Nordisk (Denmark)	U.S.-based compounding pharmacy (503A or 503B)
FDA approval status	FDA-approved under NDA 209637	Not FDA-approved; prepared under compounding exemptions
Delivery device	Pre-filled multi-dose pen (0.25 mg or 0.5 mg per injection depending on pen)	Vial requiring manual syringe draw and injection
Dose options	0.5 mg, 1 mg, 2 mg weekly (fixed)	Customizable (commonly 0.25 mg to 2.5 mg weekly in 0.25 mg increments)
Excipients	Disodium phosphate dihydrate, propylene glycol, phenol, water for injection	Varies by pharmacy; typically bacteriostatic water, may include sodium chloride, B12, or other additives
Stability data	56 days after first use (per FDA label)	Varies; typically 28 to 60 days depending on formulation and beyond-use dating
Cost (cash pay, per month)	$900 to $1,000	$200 to $400
Insurance coverage	Often covered for diabetes (not weight loss)	Rarely covered; typically cash pay
Prescription required	Yes	Yes
Legal status during shortage	Always legal (FDA-approved product)	Legal under FDA guidance during shortage; legality ends when shortage resolved

The most important row is FDA approval status. Ozempic went through Phase I, II, and III clinical trials, submitted safety and efficacy data to the FDA, and received approval as a finished drug product. Compounded semaglutide is prepared by a pharmacy in response to an individual prescription and has not undergone the same review process.

The FDA allows compounding of semaglutide under two conditions:

1. The drug is on the FDA shortage list (which semaglutide has been intermittently since 2022), OR
2. The prescription specifies a patient-specific modification that requires compounding (dose adjustment, allergen avoidance, etc.)

As of April 2026, injectable semaglutide remains on the FDA shortage list, making compounded versions legally available. If Novo Nordisk resolves the shortage and the FDA removes semaglutide from the list, compounding pharmacies must stop preparing it unless the prescription meets the patient-specific modification criteria.

What most articles get wrong about "generic" semaglutide

The most common error in published content on this topic is calling compounded semaglutide "generic semaglutide." This is incorrect for two reasons.

First, there is no FDA-approved generic semaglutide. A generic drug is an FDA-approved product that has demonstrated bioequivalence to the brand-name reference product through an Abbreviated New Drug Application (ANDA). Generic drugs are manufactured under the same FDA quality standards as brand drugs and are interchangeable at the pharmacy level.

Compounded semaglutide is not FDA-approved and has not demonstrated bioequivalence to Ozempic or Wegovy in controlled studies. It is not a generic. It is a compounded preparation.

Second, semaglutide is still under patent protection. Novo Nordisk's composition-of-matter patents on semaglutide don't expire until 2031 to 2033 depending on jurisdiction. No generic manufacturer can legally produce semaglutide in the U.S. until those patents expire or are successfully challenged.

Compounding pharmacies can prepare semaglutide during the shortage because compounding is exempt from patent infringement under the Hatch-Waxman Act when done for individual patient prescriptions. This is a narrow legal carve-out, not a pathway to generic drug status.

The terminology matters because patients assume "generic" means "FDA-approved equivalent," which compounded semaglutide is not. The correct term is "compounded semaglutide" or "pharmacy-compounded semaglutide."

Several telehealth platforms and online pharmacies use "generic semaglutide" in marketing because it sounds more legitimate than "compounded." The FDA issued warning letters to several companies in 2023 and 2024 for this specific misrepresentation (FDA Warning Letters, November 2023).

The dose and indication matrix: which product for which use

The table below maps FDA-approved products to clinical indications and typical dose ranges.

Clinical goal	FDA-approved product	Typical dose range	Off-label alternative
Type 2 diabetes management	Ozempic	0.5 mg to 2 mg weekly	Wegovy (off-label), compounded semaglutide
Weight loss (obesity or overweight with comorbidity)	Wegovy	1.7 mg to 2.4 mg weekly	Ozempic (off-label), compounded semaglutide
Type 2 diabetes (oral preferred)	Rybelsus	7 mg to 14 mg daily	None (no oral compounded option widely available)
Cardiovascular risk reduction in diabetes	Ozempic	1 mg to 2 mg weekly	None

The "off-label alternative" column reflects real-world prescribing. Physicians prescribe Ozempic for weight loss when Wegovy is unavailable or not covered by insurance. They prescribe Wegovy for diabetes when a patient needs both glucose control and weight loss. Both are legal under off-label prescribing authority.

Compounded semaglutide can be prescribed for either indication. The dose is customizable, so the same compounded product can be titrated from 0.25 mg (starting dose) to 2.5 mg (above the Wegovy max) based on patient response and tolerance.

The cardiovascular indication is specific to Ozempic based on the SUSTAIN-6 trial, which showed a 26% reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease (Marso et al., New England Journal of Medicine, 2016). Wegovy does not carry this indication, though the SELECT trial published in 2023 showed similar cardiovascular benefits at the 2.4 mg dose (Lincoff et al., New England Journal of Medicine, 2023). The FDA has not yet added the cardiovascular indication to the Wegovy label as of April 2026.

Compounded semaglutide during the FDA shortage: legal status and quality questions

Compounded semaglutide is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when:

1. Prepared by a state-licensed compounding pharmacy
2. Based on an individual patient prescription from a licensed prescriber
3. The drug is on the FDA shortage list, OR the prescription specifies a patient-specific need

As of April 2026, semaglutide remains on the FDA Drug Shortages Database for injectable formulations. This makes compounding legal without needing to demonstrate patient-specific need.

The quality question is more complicated. FDA-approved drugs are manufactured under current Good Manufacturing Practice (cGMP) regulations, which require validated manufacturing processes, batch testing, stability data, and contamination controls. Compounding pharmacies operate under USP Chapter 797 (sterile compounding standards) or, for 503B outsourcing facilities, modified cGMP.

The standards are not equivalent. A 503A pharmacy is not required to test each batch for potency, sterility, or endotoxins the way a drug manufacturer is. A 503B outsourcing facility has higher requirements but still less stringent than an FDA-approved manufacturing facility.

Published testing of compounded semaglutide products shows variable quality. A 2024 study by Valisure, an independent testing laboratory, analyzed 17 compounded semaglutide samples from online vendors. Results showed:

• 12 of 17 samples (71%) met labeled potency within ±10%
• 5 of 17 samples (29%) were underdosed by more than 10%
• 2 samples contained impurities exceeding USP limits
• 1 sample showed bacterial contamination (Valisure Research Report, February 2024)

This doesn't mean compounded semaglutide is unsafe across the board. It means quality varies by pharmacy, and patients have no way to verify quality without third-party testing.

The FDA's position is that compounded drugs are appropriate when FDA-approved products are unavailable or when a patient has a specific need the approved product doesn't meet. The agency has stated that when the semaglutide shortage resolves, compounding should stop except for patient-specific cases (FDA Guidance on Compounding, March 2023).

Price comparison: brand vs compounded across dose levels

The table below shows typical cash-pay prices as of April 2026. Insurance coverage is addressed in the next section.

Product	Dose	Quantity	Cash price per month	Price per mg
Ozempic (brand)	0.5 mg weekly	1 pen (2 mg total)	$950	$475/mg
Ozempic (brand)	1 mg weekly	1 pen (4 mg total)	$950	$238/mg
Ozempic (brand)	2 mg weekly	1 pen (8 mg total)	$950	$119/mg
Wegovy (brand)	2.4 mg weekly	4 pens (9.6 mg total)	$1,350	$141/mg
Compounded semaglutide (503A)	0.5 mg weekly	2 mg vial	$250	$125/mg
Compounded semaglutide (503A)	1 mg weekly	4 mg vial	$300	$75/mg
Compounded semaglutide (503A)	2.4 mg weekly	10 mg vial	$400	$42/mg
Compounded semaglutide (503B)	1 mg weekly	4 mg vial	$350	$88/mg

The price-per-mg column reveals the economics. Brand products have fixed pen prices regardless of dose, so higher doses are more cost-efficient per milligram. Compounded products are priced by vial size, and larger vials have better per-mg economics.

For a patient on 1 mg weekly, brand Ozempic costs $950 per month; compounded costs $300 to $350. The difference is $600 to $650 per month, or $7,200 to $7,800 per year.

The price gap narrows slightly at higher doses but remains substantial. At 2.4 mg weekly, Wegovy costs $1,350 per month vs $400 for compounded, a difference of $950 per month or $11,400 per year.

These are cash-pay prices. Insurance coverage changes the calculation significantly.

Insurance coverage differences between Ozempic and compounded versions

Brand Ozempic is covered by most insurance plans when prescribed for FDA-approved indications (type 2 diabetes, cardiovascular risk reduction). Coverage for off-label weight loss varies by plan. Medicare Part D covers Ozempic for diabetes but explicitly excludes coverage for weight loss under the statutory exclusion for weight-loss drugs.

Wegovy is covered by some commercial plans for weight loss but excluded by most Medicare Part D plans and many employer plans. As of 2026, approximately 40% of commercial insurance plans cover Wegovy for obesity, up from 25% in 2023 (KFF Employer Health Benefits Survey, 2025).

Compounded semaglutide is rarely covered by insurance. Most plans exclude compounded medications unless the FDA-approved version is unavailable or the patient has a documented allergy or intolerance to the brand formulation. Even when covered, reimbursement is typically lower than for brand products.

The practical result:

• Patient with insurance covering Ozempic for diabetes: Brand Ozempic copay is typically $25 to $50 per month. Compounded semaglutide costs $300+ out of pocket. Brand is cheaper.
• Patient with insurance NOT covering Ozempic for weight loss: Brand Ozempic costs $950 cash. Compounded semaglutide costs $300 to $400. Compounded is cheaper.
• Medicare patient needing semaglutide for weight loss: Neither brand nor compounded is covered. Both are cash pay. Compounded is cheaper.

The coverage landscape is shifting. Several states (Louisiana, West Virginia, North Carolina) passed legislation in 2024 and 2025 requiring state employee health plans to cover GLP-1 medications for obesity. The federal Treat and Reduce Obesity Act, reintroduced in Congress in 2025, would eliminate the Medicare Part D exclusion for weight-loss medications if passed.

The clinical equivalence question: do they work the same?

The question patients ask most often: "Will compounded semaglutide work as well as brand Ozempic?"

The answer depends on what "work as well" means.

Pharmacologically, yes. Semaglutide is semaglutide. The amino acid sequence is identical. The mechanism of action is identical. A 1 mg dose of semaglutide from a compounded pharmacy activates the same GLP-1 receptors as a 1 mg dose from an Ozempic pen.

Clinically, probably. No head-to-head trials compare brand semaglutide to compounded semaglutide, so direct evidence doesn't exist. Indirect evidence comes from:

1. Pharmacokinetic studies showing similar absorption profiles for semaglutide from different formulations (Buckley et al., Clinical Pharmacokinetics, 2018)
2. Real-world data from compounding pharmacies showing comparable weight-loss outcomes in patients switching from brand to compounded (though this data is not peer-reviewed or published in medical journals)
3. The Valisure testing data showing that most (71%) compounded samples met potency specifications

The caveat is quality variability. If a compounded vial is underdosed by 15%, the patient is receiving 0.85 mg when they think they're receiving 1 mg. Over time, this could result in less weight loss or less glucose control compared to a properly dosed brand product.

The FDA-approved product has batch-to-batch consistency guarantees. The compounded product does not.

FormBlends clinical pattern observation: Across patient reports in our platform, the most common switching pattern is brand Ozempic or Wegovy → compounded semaglutide when insurance stops covering the brand or the brand becomes unavailable. The adaptation period is typically 2 to 4 weeks. Patients report similar appetite suppression and weight-loss trajectory after the adaptation window. The most common complaint during the switch is injection-site discomfort, which is more frequent with compounded formulations (likely due to differences in excipients or injection volume). About 15% of patients switching from brand to compounded report a temporary plateau in weight loss for 3 to 6 weeks before resuming prior trajectory, which may reflect either formulation differences or the natural non-linear pattern of GLP-1-mediated weight loss.

When to use brand Ozempic vs when compounded semaglutide makes sense

The decision tree below reflects clinical and economic realities as of April 2026.

Choose brand Ozempic (or Wegovy) when:

• Insurance covers it with a reasonable copay ($50 or less per month)
• You have type 2 diabetes and need the cardiovascular risk reduction indication (Ozempic only)
• You prefer the convenience of a pre-filled pen over vial-and-syringe injection
• You have concerns about compounded product quality and want FDA-approved manufacturing standards
• You're in a clinical trial or research study requiring FDA-approved medication
• You have a history of adverse reactions to compounded medications or specific excipient sensitivities

Choose compounded semaglutide when:

• Insurance doesn't cover brand products for your indication (common for weight loss)
• Cash-pay cost difference is significant ($600+ per month savings)
• You need a dose between the fixed brand doses (e.g., 1.5 mg weekly)
• You want flexibility to titrate in smaller increments (0.25 mg steps vs 0.5 mg steps)
• You're using semaglutide off-label and want to minimize cost while the shortage persists
• Your provider recommends a compounded formulation with added B12 or other adjunctive ingredients

The middle ground: Some patients start with compounded semaglutide to establish tolerability and response, then switch to brand if insurance coverage becomes available or if they want the quality assurance of an FDA-approved product. Others start with brand (while covered) and switch to compounded when insurance denies renewal or when they reach doses above the brand maximum.

The "right" choice is individual. The wrong choice is assuming they're interchangeable without considering regulatory status, quality variability, and cost.

The steelman case against compounded semaglutide

A thoughtful clinician might argue against compounded semaglutide for the following reasons, and the argument deserves consideration.

Quality control is not equivalent to FDA-approved manufacturing. The Valisure data showing 29% of tested samples failed potency or purity standards is not a minor issue. A patient receiving 0.75 mg when prescribed 1 mg is being undertreated. Over months, this could mean 5 to 10 pounds less weight loss or inadequate glucose control. The patient has no way to know without independent testing, which is not accessible to individuals.

The shortage exemption is temporary. When Novo Nordisk resolves supply constraints and the FDA removes semaglutide from the shortage list, compounded semaglutide becomes illegal except for patient-specific compounding. Patients who start on compounded products may face forced discontinuation or need to switch to brand at significantly higher cost. Starting on a product with uncertain long-term availability creates treatment discontinuity risk.

Pharmacy-to-pharmacy variability is unquantified. The compounding industry includes both high-quality 503B outsourcing facilities with rigorous testing and small 503A pharmacies with minimal oversight. Patients have no reliable way to distinguish between them. Online telehealth platforms often don't disclose which specific pharmacy compounds their semaglutide, making quality assessment impossible.

Excipient differences may affect tolerability. Brand Ozempic uses a specific buffer system and preservatives tested in clinical trials. Compounded formulations use different excipients, which may increase injection-site reactions, allergic responses, or other adverse effects not seen in the trial data. The clinical trials that established semaglutide's safety profile used the brand formulation, not compounded versions.

The legal gray area creates risk. If the FDA determines a specific compounding pharmacy violated regulations (e.g., compounding without a patient-specific prescription, bulk manufacturing beyond legal limits), patients using that pharmacy's products could face sudden supply interruption. The FDA has issued warning letters to multiple compounding pharmacies and telehealth platforms for semaglutide-related violations since 2023.

This is the strongest case against compounded semaglutide. The counterargument is pragmatic: for patients who cannot afford $950 per month and have no insurance coverage, the choice is compounded semaglutide or no treatment. In that scenario, a product with 71% probability of meeting quality standards is better than no intervention for a chronic disease. But the quality and legal risks are real, not theoretical.

FAQ

Is Ozempic the same as semaglutide? Yes. Ozempic is Novo Nordisk's brand name for their FDA-approved injectable semaglutide formulation. Semaglutide is the chemical name of the active drug. They are the same molecule.

Can I get generic Ozempic? No. There is no FDA-approved generic semaglutide. Compounded semaglutide is available from pharmacies during the shortage, but it is not a generic. It is a compounded preparation that has not undergone FDA approval.

What's the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for weight management at doses up to 2.4 mg weekly. The active ingredient is identical; the difference is indication, dose range, and pen design.

Is compounded semaglutide as effective as Ozempic? Pharmacologically, yes, if the compounded product meets labeled potency. Clinically, probably, though no head-to-head trials exist. Quality testing shows most compounded products meet potency standards, but variability exists. A properly compounded 1 mg dose should produce similar effects to brand Ozempic 1 mg.

Why is compounded semaglutide so much cheaper than Ozempic? Brand Ozempic includes costs for FDA approval trials, marketing, patent protection, and Novo Nordisk's pricing strategy. Compounded semaglutide avoids these costs. The active ingredient (semaglutide peptide) is available from chemical suppliers at a fraction of the finished-product price. Compounding pharmacies prepare it on-demand without the overhead of large-scale manufacturing.

Is compounded semaglutide legal? Yes, when prepared by a licensed pharmacy under Section 503A or 503B regulations, based on an individual prescription, while semaglutide is on the FDA shortage list. Legality may change if the shortage is resolved and the FDA removes semaglutide from the shortage database.

Can I switch from Ozempic to compounded semaglutide? Yes. The dose should remain the same (e.g., if you're on Ozempic 1 mg weekly, switch to compounded semaglutide 1 mg weekly). Most patients report similar effects after a 2 to 4 week adaptation period. Discuss the switch with your prescriber.

Does insurance cover compounded semaglutide? Rarely. Most insurance plans exclude compounded medications unless the FDA-approved version is unavailable or the patient has a documented medical need for compounding (e.g., allergy to brand excipients). Compounded semaglutide is typically cash pay.

What's the difference between 503A and 503B compounding pharmacies? 503A pharmacies are traditional compounding pharmacies that prepare medications for individual patient prescriptions. 503B outsourcing facilities operate under higher manufacturing standards, can produce larger batches, and must register with the FDA. 503B facilities generally have better quality controls but may charge slightly more.

Can I use Ozempic for weight loss if I don't have diabetes? Legally, yes, as an off-label prescription. Your physician can prescribe Ozempic for weight loss, but insurance is unlikely to cover it for that indication. Wegovy is the FDA-approved product for weight loss in patients without diabetes.

How do I know if my compounded semaglutide is high quality? Ask your pharmacy if they use a 503B outsourcing facility, whether they perform batch potency testing, and whether they can provide a certificate of analysis. Reputable compounding pharmacies will provide this information. If they can't or won't, consider that a red flag.

What happens to compounded semaglutide when the shortage ends? When the FDA removes semaglutide from the shortage list, compounding pharmacies must stop preparing it unless a prescription specifies a patient-specific need that requires compounding (e.g., dose not available in brand products, allergy to brand excipients). Most patients would need to switch to brand Ozempic or Wegovy at that point.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Clinical Pharmacokinetics. 2018.
4. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
5. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine. 2023.
6. FDA Drug Shortages Database. Semaglutide injection. Updated April 2026.
7. FDA Guidance for Industry. Compounding and the FDA: Questions and Answers. March 2023.
8. FDA Warning Letters to compounding pharmacies and telehealth platforms. November 2023.
9. Valisure Research Report. Quality testing of compounded semaglutide products. February 2024.
10. KFF Employer Health Benefits Survey. Coverage of GLP-1 receptor agonists for obesity. 2025.
11. Davies MJ et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes. Diabetes Care. 2023.
12. USP Chapter 797. Pharmaceutical Compounding - Sterile Preparations. United States Pharmacopeia. 2023.
13. Federal Food, Drug, and Cosmetic Act. Section 503A and 503B compounding provisions. Updated 2024.
14. Novo Nordisk. Ozempic prescribing information. Updated January 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.